Confo Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$65M
- Investors
-
19
Confo Therapeutics General Information
Description
Developer of a drug discovery company intended to discover drugs for single-domain antibodies. The company is building a portfolio of programs based on its proprietary technology which derives specialized camelid single-domain antibodies that stabilize G-protein coupled receptors (GPCRs) in a conformation of interest for drug discovery, enabling the medical industry with novel agonists for improved therapeutic intervention.
Contact Information
Website
www.confotherapeutics.comCorporate Office
- Technologiepark 30
- Zwijnaarde
- 9052 Ghent
- Belgium
Corporate Office
- Technologiepark 30
- Zwijnaarde
- 9052 Ghent
- Belgium
Confo Therapeutics Timeline
Confo Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
11. Later Stage VC (Series B) | 26-Jul-2024 | $65M | Completed | Clinical Trials - Phase 1 | ||
10. Grant | 28-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
9. Grant | 28-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
8. Grant | 30-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
7. Grant | 20-Jun-2019 | Completed | Clinical Trials - Phase 1 | |||
6. Early Stage VC (Series A) | 01-May-2019 | Completed | Clinical Trials - Phase 1 | |||
5. Grant | 20-Feb-2018 | Completed | Clinical Trials - Phase 1 | |||
4. Grant | 01-Feb-2017 | Completed | Clinical Trials - Phase 1 | |||
3. Early Stage VC | 01-Feb-2016 | $7.28M | $7.28M | Completed | Clinical Trials - Phase 1 | |
2. Accelerator/Incubator | 01-Jan-2015 | Completed | Startup |
Confo Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Class B2 | ||||||||
Class B |
Confo Therapeutics Comparisons
Industry
Financing
Details
Confo Therapeutics Competitors (89)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
Agenus | Formerly VC-backed | Lexington, MA | ||||
InterAx | Venture Capital-Backed | Villigen, Switzerland |
Confo Therapeutics Patents
Confo Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3227194-A1 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | Pending | 30-Jul-2021 | ||
AU-2022318349-A1 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | Pending | 30-Jul-2021 | ||
EP-4377307-A1 | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | Pending | 30-Jul-2021 | ||
EP-3963328-A1 | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs | Pending | 29-Apr-2019 | ||
EP-3963329-A1 | Screening methods and assays for use with transmembrane proteins, in particular with gpcrs | Pending | 29-Apr-2019 | G01N33/566 |
Confo Therapeutics Signals
Confo Therapeutics Investors (19)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Ackermans & van Haaren | Growth/Expansion | Minority | ||
Driehaus Capital Management | Corporation | Minority | ||
Quest For Growth | Asset Manager | Minority | ||
BioGeneration Ventures | Venture Capital | Minority | ||
Fund+ | Venture Capital | Minority |
Confo Therapeutics FAQs
-
When was Confo Therapeutics founded?
Confo Therapeutics was founded in 2015.
-
Where is Confo Therapeutics headquartered?
Confo Therapeutics is headquartered in Ghent, Belgium.
-
What is the size of Confo Therapeutics?
Confo Therapeutics has 66 total employees.
-
What industry is Confo Therapeutics in?
Confo Therapeutics’s primary industry is Drug Discovery.
-
Is Confo Therapeutics a private or public company?
Confo Therapeutics is a Private company.
-
What is Confo Therapeutics’s current revenue?
The current revenue for Confo Therapeutics is
. -
How much funding has Confo Therapeutics raised over time?
Confo Therapeutics has raised $105M.
-
Who are Confo Therapeutics’s investors?
Ackermans & van Haaren, Driehaus Capital Management, Quest For Growth, BioGeneration Ventures, and Fund+ are 5 of 19 investors who have invested in Confo Therapeutics.
-
Who are Confo Therapeutics’s competitors?
CytomX Therapeutics, Inhibrx, CRISPR Therapeutics, Agenus, and InterAx are some of the 89 competitors of Confo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »